Concepedia

Peter Schmid

PS

133

Publications

22K

Citations

57

H-Index

2007

Active since

Affiliations

Queen Mary University of London(Current)

Peter MacCallum Cancer Centre

Dana-Farber Cancer Institute

Vall d'Hebron Institute of Oncology

Merck & Co., Inc., Rahway, NJ, USA (United States)

Peter Schmid is an author at Queen Mary University of London specializing in oncology, medicine, and cancer therapeutics.

Top concepts

MedicineOncologyCancer TherapyBreast CancerRadiation OncologyPathologyMolecular OncologyPharmacologyPharmacotherapyCancer Research

Publications per year

2007–2025

133

Publications

133

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.2K citations · Full text

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 2.9K citations · Full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

Chemotherapy Versus Placebo, Breast Oncology, Oncology +7

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology · 2019 · 1.2K citations

Breast Oncology, Oncology, Medicine +7

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 968 citations · Full text

Rows per page

1–5 of 133